Story · Medicine & Biotech

Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio

1 outlet · first reported by BioSpectrum India on

Biocon has announced that the US Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar of the reference product Perjeta® (pertuzumab). PEBRILZO is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer… (BioSpectrum India)

Coverage, in order

  1. BioSpectrum India India indie
    Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio

    Biocon has announced that the US Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar of the reference product Perjeta® (pertuzumab). PEBRILZO is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.